Sung H. Bae

Daegu, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Prognostic Value of Qualitative Splenic [18F]FDG Uptake on Baseline PET/CT in Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Prognostic Value of Qualitative Splenic [18F]FDG Uptake on Baseline PET/CT in Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Journal: Cancers

Published: December 19, 2025

Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Journal: The Korean journal of internal medicine

Published: October 17, 2025

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Journal: Therapeutic advances in hematology

Published: October 05, 2025

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Journal: The Lancet. Haematology

Published: June 11, 2025

Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.

Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.

Journal: Haematologica

Published: March 20, 2025

Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study.

Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study.

Journal: Cancer research and treatment

Published: January 15, 2025

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.

Journal: International journal of cancer

Published: October 03, 2024

Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.

Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.

Journal: British journal of haematology

Published: April 05, 2024

The characteristics of Korean elderly multiple myeloma patients aged 80 years or over.

The characteristics of Korean elderly multiple myeloma patients aged 80 years or over.

Journal: The Korean journal of internal medicine

Published: February 08, 2024

Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients.

Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients.

Journal: Journal of Korean medical science

Published: July 11, 2023

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma.

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma.

Journal: The Korean journal of internal medicine

Published: June 09, 2023

Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).

Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).

Journal: Annals of hematology

Published: February 16, 2023

Showing 1-12 of 74

Last Updated: 09/26/2026